✨ Unlock Data Exports And Disclosure Access.Start Your 30-Day Free Trial Today →

Chengdu Kanghong Pharmaceutical Group Co Ltd

Common Name
Chengdu Kanghong Pharmaceutical Group
Country
China (Mainland)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
4,289
Ticker
002773
Exchange
Shenzhen Stock Exchange
Description
Chengdu Kanghong Pharmaceutical Co., Ltd. is a leading enterprise in the pharmaceutical industry, specializing in the research, development, manufacturing, and distribution of specialty pharmaceutical...

Chengdu Kanghong Pharmaceutical Group's GHG Emissions Data Preview

In 2025, Chengdu Kanghong Pharmaceutical Group completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).

However, Chengdu Kanghong Pharmaceutical Group has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)2025202420232022-2019
Total Scope 1
11,554.686a
12,940.6a
12,008.835a
Total Scope 2
Unspecified Calculation Method
4,696.212a
4,993.08a
4,680.381a
Total Scope 3
N/AN/AN/A
Total Scope 1 Revenue Intensity (tCO2e/$M)
17.6423a
21.2102a
21.5661a
Usage Policy

You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"

Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.

Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=002773&reporting_period=2025"

Verified Sources Behind Chengdu Kanghong Pharmaceutical Group’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.

a. Chengdu Kanghong Pharmaceutical Group's Responsibility Report 2025
a. Chengdu Kanghong Pharmaceutical Group's Responsibility Report 2025

Insights into Chengdu Kanghong Pharmaceutical Group's Operational Emissions

In 2025, the total operational greenhouse gas (GHG) emissions of Chengdu Kanghong Pharmaceutical Group amounted to 16,250.898 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2024, the total operational greenhouse gas (GHG) emissions of Chengdu Kanghong Pharmaceutical Group decreased by 9.38%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a

Chengdu Kanghong Pharmaceutical Group's Scope 1 Emissions Over Time

20232024202503.5 k7 k10.5 k14 ktCO2e+8%-11%
  • Total Scope 1
  • Year-over-Year Change

What are Chengdu Kanghong Pharmaceutical Group's Scope 1 emissions?

In 2025, the total Scope 1 emissions of Chengdu Kanghong Pharmaceutical Group were 11,554.686 metric tons of CO₂ equivalent (tCO₂e).a

Has Chengdu Kanghong Pharmaceutical Group reduced its Scope 1 emissions over time?

Since 2023, Chengdu Kanghong Pharmaceutical Group's Scope 1 emissions have decreased by 3.78%, reflecting a declining long-term trend in Scope 1 emissions over time.a

Compared to the previous year (2024), Chengdu Kanghong Pharmaceutical Group's Scope 1 emissions decreased by 10.71%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a

What are Chengdu Kanghong Pharmaceutical Group's Scope 2 emissions?

In 2025, Chengdu Kanghong Pharmaceutical Group reported Scope 2 greenhouse gas (GHG) emissions of 4,696.212 tCO₂e without specifying the calculation method.a

Has Chengdu Kanghong Pharmaceutical Group reduced its Scope 2 emissions over time?

Since 2023, Chengdu Kanghong Pharmaceutical Group's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Chengdu Kanghong Pharmaceutical Group's emissions have plateaued with no significant change in its energy consumption footprint.a

Compared to the previous year (2024), Chengdu Kanghong Pharmaceutical Group's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Chengdu Kanghong Pharmaceutical Group's emissions have plateaued with no significant change in its energy consumption footprint.a

What methodology does Chengdu Kanghong Pharmaceutical Group use for Scope 2 reporting?

In 2025, Chengdu Kanghong Pharmaceutical Group reported its Scope 2 emissions using an unspecified methodology.a

Chengdu Kanghong Pharmaceutical Group's Scope 2 Emissions Over Time

20232024202501.5 k3 k4.5 k6 ktCO2e
  • Total Scope 2 (Unspecified Calculation Method)

Insights into Chengdu Kanghong Pharmaceutical Group’s GHG Emissions Intensity Compared to Industry Peers

In 2025, Chengdu Kanghong Pharmaceutical Group reported Scope 1 greenhouse gas (GHG) emissions of 11,554.686 tCO₂e and total revenues of USD 655 millions. This translates into an emissions intensity of 17.64 tCO₂e per millions USD.a

Chengdu Kanghong Pharmaceutical Group's Scope 1 Emissions Intensity Compared to Peers

2002,00020,000200,0005,000,000Scope 1 Emissions (tCO2e)502001,0002,00010,000Revenues (Millions of USD)Zhejiang NhuYear: 2025Scope 1: 897,516 tCO2eRevenue: $M 3,178Scope 1 Intensity: 282.38 tCO2e/$MYunnan Baiyao GroupYear: 2025Scope 1: 34,719 tCO2eRevenue: $M 5,883Scope 1 Intensity: 5.90 tCO2e/$MHansoh Pharmaceutical GroupYear: 2025Scope 1: 11,834 tCO2eRevenue: $M 2,147Scope 1 Intensity: 5.51 tCO2e/$MJiangsu Hengrui PharmaceuticalsYear: 2025Scope 1: 54,874 tCO2eRevenue: $M 4,518Scope 1 Intensity: 12.15 tCO2e/$MLuye Pharma GroupYear: 2023Scope 1: 10,755 tCO2eRevenue: $M 864Scope 1 Intensity: 12.44 tCO2e/$MCanSino BiologicsYear: 2025Scope 1: 2,121 tCO2eRevenue: $M 151Scope 1 Intensity: 14.02 tCO2e/$MJoincareYear: 2025Scope 1: 219,583 tCO2eRevenue: $M 2,173Scope 1 Intensity: 101.03 tCO2e/$MCR Double-CraneYear: 2024Scope 1: 58,155 tCO2eRevenue: $M 1,536Scope 1 Intensity: 37.86 tCO2e/$MTasly Pharmaceutical GroupYear: 2024Scope 1: 37,370 tCO2eRevenue: $M 1,164Scope 1 Intensity: 32.09 tCO2e/$MApeloa PharmaceuticalYear: 2025Scope 1: 75,760 tCO2eRevenue: $M 1,397Scope 1 Intensity: 54.21 tCO2e/$MZhejiang Huahai PharmaceuticalYear: 2024Scope 1: 58,691 tCO2eRevenue: $M 1,308Scope 1 Intensity: 44.86 tCO2e/$MLivzon Pharmaceutical GroupYear: 2025Scope 1: 175,562 tCO2eRevenue: $M 1,717Scope 1 Intensity: 102.25 tCO2e/$MDizal PharmaceuticalYear: 2025Scope 1: 887 tCO2eRevenue: $M 114Scope 1 Intensity: 7.75 tCO2e/$MPorton Pharma SolutionsYear: 2025Scope 1: 9,489 tCO2eRevenue: $M 488Scope 1 Intensity: 19.43 tCO2e/$MDa Ren TangYear: 2025Scope 1: 3,870 tCO2eRevenue: $M 702Scope 1 Intensity: 5.51 tCO2e/$MShenzhen Salubris PharmaceuticalsYear: 2024Scope 1: 11,399 tCO2eRevenue: $M 550Scope 1 Intensity: 20.73 tCO2e/$MSichuan Biokin PharmaceuticalYear: 2025Scope 1: 8,090 tCO2eRevenue: $M 360Scope 1 Intensity: 22.48 tCO2e/$MSihuan PharmaceuticalYear: 2023Scope 1: 45,602 tCO2eRevenue: $M 262Scope 1 Intensity: 174.19 tCO2e/$MConsun Pharmaceutical GroupYear: 2025Scope 1: 7,133 tCO2eRevenue: $M 488Scope 1 Intensity: 14.61 tCO2e/$MZhejiang Jiuzhou PharmaceuticalYear: 2025Scope 1: 57,658 tCO2eRevenue: $M 787Scope 1 Intensity: 73.28 tCO2e/$MHepalinkYear: 2025Scope 1: 13,483 tCO2eRevenue: $M 777Scope 1 Intensity: 17.36 tCO2e/$MBioKangtaiYear: 2025Scope 1: 15,001 tCO2eRevenue: $M 382Scope 1 Intensity: 39.29 tCO2e/$MBetta PharmaceuticalsYear: 2025Scope 1: 1,268 tCO2eRevenue: $M 516Scope 1 Intensity: 2.46 tCO2e/$MWalvax BiotechnologyYear: 2024Scope 1: 7,643 tCO2eRevenue: $M 387Scope 1 Intensity: 19.77 tCO2e/$MChengdu Kanghong Pharmaceutical GroupYear: 2025Scope 1: 11,555 tCO2eRevenue: $M 655Scope 1 Intensity: 17.64 tCO2e/$M

How does Chengdu Kanghong Pharmaceutical Group's GHG emissions intensity compare to its peers?

In 2025, Chengdu Kanghong Pharmaceutical Group reported a Scope 1 emissions intensity of 17.64 tCO₂e per millions USD. Compared to the peer group median of 20.25, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a

Where does Chengdu Kanghong Pharmaceutical Group rank on GHG emissions intensity within its industry?

In 2025, Chengdu Kanghong Pharmaceutical Group ranked 11 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

Chengdu Kanghong Pharmaceutical Group is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a

Want Full Access to Chengdu Kanghong Pharmaceutical Group's GHG Emissions Dataset?
Start 30-Day Free Trial